JO
ALDX icon

John Overdeck’s Aldeyra Therapeutics ALDX Stock Holding History

John Overdeck’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Sell
127,849
-95,688
-43% -$164K ﹤0.01% 4592
2026
Q1 		$378K Sell
223,537
-63,827
-22% -$280K ﹤0.01% 3912
2025
Q4 		$1.49M Buy
287,364
+14,310
+5% +$73.5K ﹤0.01% 2666
2025
Q3 		$1.43M Buy
273,054
+217,315
+390% +$1.13M ﹤0.01% 2350
2025
Q2 		$213K Buy
55,739
+412
+0.7% +$1.06K ﹤0.01% 2898
2025
Q1 		$318K Sell
55,327
-76,083
-58% -$450K ﹤0.01% 2689
2024
Q4 		$656K Sell
131,410
-15,349
-10% -$78.8K ﹤0.01% 2405
2024
Q3 		$791K Sell
146,759
-46,356
-24% -$221K ﹤0.01% 2248
2024
Q2 		$639K Sell
193,115
-45,849
-19% -$180K ﹤0.01% 2240
2024
Q1 		$781K Buy
238,964
+37,423
+19% +$123K ﹤0.01% 2104
2023
Q4 		$707K Sell
201,541
-65,781
-25% -$203K ﹤0.01% 2275
2023
Q3 		$1.79M Buy
267,322
+136,022
+104% +$1.01M ﹤0.01% 1481
2023
Q2 		$1.1M Sell
131,300
-89,200
-40% -$879K ﹤0.01% 1895
2023
Q1 		$2.19M Sell
220,500
-230,187
-51% -$1.63M 0.01% 1332
2022
Q4 		$3.14M Sell
450,687
-130,752
-22% -$748K 0.01% 1091
2022
Q3 		$3.1M Sell
581,439
-24,629
-4% -$148K 0.01% 960
2022
Q2 		$2.42M Buy
606,068
+263,181
+77% +$905K 0.01% 1097
2022
Q1 		$1.52M Sell
342,887
-334,185
-49% -$1.33M ﹤0.01% 1480
2021
Q4 		$2.71M Sell
677,072
-119,153
-15% -$909K 0.01% 1653
2021
Q3 		$6.99M Sell
796,225
-334,509
-30% -$3.07M 0.02% 984
2021
Q2 		$12.8M Buy
1,130,734
+248,772
+28% +$2.99M 0.03% 679
2021
Q1 		$10.5M Buy
881,962
+215,593
+32% +$2.48M 0.03% 691
2020
Q4 		$4.57M Sell
666,369
-3,465
-0.5% -$24.3K 0.01% 987
2020
Q3 		$4.96M Buy
669,834
+496,101
+286% +$3.2M 0.02% 796
2020
Q2 		$724K Buy
173,733
+95,173
+121% +$348K ﹤0.01% 1748
2020
Q1 		$194K Buy
+78,560
New +$353K ﹤0.01% 2664
2018
Q4 		– Sell
-40,929
Closed -$565K – 2939
2018
Q3 		$565K Buy
+40,929
New +$332K ﹤0.01% 2365

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

John Overdeck's ALDX Position: Q2 2026 in Review

John Overdeck reduced its Aldeyra Therapeutics (ALDX) stake by 43% in Q2 2026, selling an estimated $164K and leaving 127,849 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #4592.

John Overdeck first reported a position in ALDX in Q3 2018 and has held it in 27 quarters since. The position peaked at $12.8M in Q2 2021. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • John Overdeck held 127,849 shares of Aldeyra Therapeutics worth $272K as of Q2 2026.
  • John Overdeck sold 95,688 Aldeyra Therapeutics shares in Q2 2026, an estimated $164K.
  • Aldeyra Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4592 holding.
  • John Overdeck first reported a position in Aldeyra Therapeutics in Q3 2018 and has held it in 27 quarters since.
  • John Overdeck's Aldeyra Therapeutics position peaked at $12.8M in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.